Premenstrual syndrome. Pathogenetic aspects of treatment

Posted by: Т.F. Tatarchuk,  Doctor of Medical Sciences (MD), Full Professor, Associate Member of the National Academy of Medical Sciences of Ukraine,  Doctor of Medical Sciences (MD), N.F. Zakharenko, I.P. Manoliak. Place of publication: Reproductive Endocrinology № 5 (43) November 2018. Summary: The purpose of the study described in the article was to study the effectiveness of the use of micronized progesterone in the treatment of the premenstrual syndrome. 68 women of reproductive age from 18 to 40 years (mean age 31.2 ± 5.3 years) with the premenstrual syndrome of mild and moderate severity were examined. The study women were randomized into two groups: treatment group (n = 35) and control group (n = 33). Study groups were matched for age and forms of premenstrual syndrome. The patients in the treatment group received treatment with Proginorm OVO 200 mg daily for 16 to 25 days of the menstrual cycle for...

Treatment and prevention of obstetric and perinatal complications in pregnant women with uterine leiomyoma.

Posted by: H.B. Semenyna, H.Yu. Fedoriv, 1. Danylo Halytsky Lviv National Medical University (Department of Obstetrics and Gynecology, Head of the Department Doctor of Medical Sciences, Professor, Member of NAMS of Ukraine, Honored Worker of Science and Technology of Ukraine Leonid Borysovych Markin), 2. Lviv Regional Clinical Hospital. Place of publication: Reproductive Health. Eastern Europe. 2018, Volume 8, № 4.

New dosage forms of micronized progesterone - the basis for the correction of the reproductive problems of the female body

Posted by: V.V. Bobritskaya, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine. Publication: Reproductive Health. Eastern Europe. 2017, Volume 7, No 4. Summary: The data of an analytical review of the effectiveness of the use of micronized progesterone in various clinical situations are presented: from the beginning of the reproductive period to menopause. According to international consensus, vaginal forms of micronized progesterone are defined as the most effective (along with injectable dosage forms) in cases of threatened preterm birth, habitual miscarriage, in assisted reproductive technology programs. Oral and vaginal dosage forms are recommended in the presence of menstrual irregularities, accompanied by luteal phase insufficiency, the menopausal period in the hormone replacement therapy complex. The new generation micronized progesterone Proginorm Gest for vaginal use and Proginorm OVO for oral use, at a dosage of 100 and 200 mg, are optimal drugs that fully comply with the requirements of domestic and international...